|Day Low/High||240.02 / 246.84|
|52 Wk Low/High||177.05 / 264.97|
Try this bearishly biased, out-of-the-money put spread on the Nasdaq 100 ETF.
The stock is set up well for more upside and remains very near a low-risk buy zone.
The tactic is the bearishly biased, calendar diagonal call spread, which controls the risk of the trade.
"Success breeds complacency. Complacency breeds failure. Only the paranoid survive." - Andy Grove Perhaps this qualifies as a potential warning from "Uncle" Bob Farrell's ten lessons of investing. Frankly, I thought dumping Ford's Fields was idi...
Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating
Better-than-expected earnings from PayPal drove the Nasdaq to new records, while a slump in crude oil kneecaps any big gains for the rest of the market.
It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...
You think the exchange is overvalued? I don't, and here's why.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer sheds light on what's next for Amgen AMGN shares following its downgrade by Jefferies.
Get your plan in place, but understand that the Republic is not in jeopardy.
Here's a rundown of four technical setups that are showing solid trading potential.
Stocks churn around the flatline to end the week as a selloff in health care counters gains seen elsewhere.
Today's session is reminiscent of a pre-Trump day.
Stocks creep lower on Friday as a selloff in health care extends into its second day, this time led by Amgen shares.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer discusses Friday's most talked about stocks including Adobe Systems, Amgen, Canada Goose, Costco and Starbucks.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer doesn't want to give up on Amgen.
Repatha costs $14,000 per year before discounts.
This reversal has been incredible to watch.
TheStreet's Jim Cramer discusses Wednesday's trending stocks.
Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...
Why the name is sagging, and what it will take to spur the sector higher.
Jim Cramer says no one really knows what President Trump means when it comes to drug pricing.
Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.
The 50-day moving average is crossing the 200-day for a bullish golden cross; go long here.